Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$17.01 +1.3%	$17.66	$13.53 ▼ $35.25	$1.69B	2.09	1.49 million shs	1.53 million shs
BVNRY Bavarian Nordic	$8.81 -0.2%	$8.52	$6.60 ▼ $14.60	$2.09B	1.36	3,744 shs	1,256 shs
NSTG NanoString Technologies		$0.36	$0.05 ▼ $11.78	$5.07M	1.24	34.54 million shs	23.06 million shs
PASG Passage Bio	$0.40 +20.9%	$0.37	$0.26 ▼ $1.33	$20.58M	1.71	372,795 shs	606,213 shs
SRNE Sorrento Therapeutics	$0.00 -36.4%	$0.00	$0.00 ▼ $0.02	$772K	0.97	89,016 shs	146,709 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+1.25%	+1.80%	+8.07%	-3.57%	-27.40%
BVNRY Bavarian Nordic	-0.17%	+1.73%	+2.04%	+20.11%	+6.66%
NSTG NanoString Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
PASG Passage Bio	+20.90%	+19.56%	-6.93%	+3.70%	-49.60%
SRNE Sorrento Therapeutics	-36.36%	-36.36%	+7.69%	+40.00%	-85.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.3086 of 5 stars	3.5	1.0	0.0	0.0	2.2	2.5	0.6
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NSTG NanoString Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	2.8484 of 5 stars	3.5	3.0	0.0	0.0	1.6	1.7	1.3
SRNE Sorrento Therapeutics	0.6008 of 5 stars	0.0	2.0	0.0	4.1	0.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	186.60% Upside
BVNRY Bavarian Nordic	0.00	N/A	N/A	N/A
NSTG NanoString Technologies	0.00	N/A	N/A	N/A
PASG Passage Bio	3.00	Buy	$7.50	1,773.59% Upside
SRNE Sorrento Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SRNE, PASG, NSTG, BEAM, and BVNRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	26.93	N/A	N/A	$8.86 per share	1.92
BVNRY Bavarian Nordic	$829.12M	2.51	$1.01 per share	8.71	$6.99 per share	1.26
NSTG NanoString Technologies	$127.26M	0.00	N/A	N/A	$0.98 per share	0.00
PASG Passage Bio	N/A	N/A	N/A	N/A	$0.99 per share	N/A
SRNE Sorrento Therapeutics	$60.32M	0.01	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
BVNRY Bavarian Nordic	$143.26M	$0.80	11.01	8.39	N/A	21.11%	11.89%	9.32%	8/22/2025 (Estimated)
NSTG NanoString Technologies	-$159.54M	-$3.53	N/A	N/A	N/A	-102.44%	-548.25%	-53.79%	N/A
PASG Passage Bio	-$64.77M	-$1.02	N/A	N/A	N/A	N/A	-93.59%	-59.65%	8/14/2025 (Estimated)
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SRNE, PASG, NSTG, BEAM, and BVNRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	PASG Passage Bio	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/9/2025	Q1 2025	BVNRY Bavarian Nordic	N/A	$0.13	N/A	$0.13	N/A	$189.89 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A
NSTG NanoString Technologies	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
BVNRY Bavarian Nordic	N/A	2.81	1.44
NSTG NanoString Technologies	N/A	2.73	2.02
PASG Passage Bio	N/A	3.74	3.74
SRNE Sorrento Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
BVNRY Bavarian Nordic	N/A
NSTG NanoString Technologies	N/A
PASG Passage Bio	53.48%
SRNE Sorrento Therapeutics	0.02%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
BVNRY Bavarian Nordic	N/A
NSTG NanoString Technologies	3.10%
PASG Passage Bio	5.00%
SRNE Sorrento Therapeutics	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
BVNRY Bavarian Nordic	1,611	236.57 million	N/A	Not Optionable
NSTG NanoString Technologies	550	48.12 million	46.63 million	Optionable
PASG Passage Bio	130	62.15 million	59.48 million	Optionable
SRNE Sorrento Therapeutics	800	551.28 million	536.95 million	No Data

SRNE, PASG, NSTG, BEAM, and BVNRY Headlines

Recent News About These Companies

SRNE Sorrento Therapeutics, Inc. - Seeking Alpha

June 29 at 8:35 AM | seekingalpha.com

Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | Benzinga

April 19, 2025 | benzinga.com

Sorrento Shareholders Lose Discovery Bid Over Judge Relationship

March 28, 2025 | news.bloomberglaw.comN

Scilex says bankruptcy court extends lockup period on shares of Scilex dividend

January 31, 2025 | markets.businessinsider.com

DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills

October 24, 2024 | newsfilecorp.comN

Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says

August 20, 2024 | msn.com

Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter

May 29, 2024 | newsfilecorp.comN

Sorrento Therapeutics Inc (SRNE)

May 25, 2024 | investing.com

Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person

May 8, 2024 | newsfilecorp.comN

DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing

May 1, 2024 | newsfilecorp.comN

Sorrento Therapeutics Inc SRNE

April 26, 2024 | morningstar.comM

Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks

March 27, 2024 | news.bloomberglaw.comN

Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks

March 27, 2024 | news.bloomberglaw.comN

Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)

March 12, 2024 | news.bloomberglaw.comN

Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case

March 12, 2024 | wsj.com

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

February 27, 2024 | tmcnet.com

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

February 27, 2024 | businesswire.com

Sorrento Therapeutics

February 7, 2024 | pharmaphorum.comP

5 Sanders Cove, Sorrento WA 6020

January 18, 2024 | domain.com.auD

Sorrento Therapeutics, Inc. (0L85.L)

January 9, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRNE, PASG, NSTG, BEAM, and BVNRY Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$17.01 +0.21 (+1.25%)

As of 06/30/2025 04:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Bavarian Nordic OTCMKTS:BVNRY

$8.81 -0.02 (-0.17%)

As of 06/30/2025 01:28 PM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

NanoString Technologies NASDAQ:NSTG

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Passage Bio NASDAQ:PASG

$0.40 +0.07 (+20.90%)

As of 06/30/2025 04:00 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Sorrento Therapeutics NASDAQ:SRNE

$0.0014 0.00 (-36.36%)

As of 06/30/2025 03:51 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time